An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Domain Therapeutics Appoints Dr Xavier Leroy as Chief Scientific Officer
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags
management
Rhea-AI Summary
Domain Therapeutics has appointed Dr. Xavier Leroy as Chief Scientific Officer (CSO), enhancing its leadership in immuno-oncology and GPCR programs. Previously serving as Chief Technology Officer, Dr. Leroy will now oversee research and the transition of the company to a clinical-stage biopharmaceutical entity. He highlights the opportunity to develop first-in-class candidates targeting new GPCRs. Dr. Leroy's extensive experience includes senior roles at Actelion Pharmaceuticals and significant contributions to raising $75M in funding for immuno-oncology projects.
Positive
Appointment of Dr. Xavier Leroy as CSO expected to strengthen leadership and accelerate the transition to a clinical-stage biotech.
Dr. Leroy's extensive expertise in GPCRs and immunology positions the company to advance its innovative immuno-oncology pipeline.
Negative
Potential concerns regarding continuity in leadership as the company transitions to a clinical stage, given the significant responsibilities now placed on Dr. Leroy.
Dr Leroy will oversee the pipeline of the company in immuno-oncology and will be responsible for advancing the GPCR programs to the clinic
STRASBOURG, France & MONTREAL, Canada--(BUSINESS WIRE)--
Domain Therapeutics, a biopharmaceutical company specializing in the research and development of innovative drugs targeting G Protein-Coupled Receptors (GPCRs) in immuno-oncology (IO), today announced that it is strengthening its scientific team with the appointement of Dr Xavier Leroy as CSO.
Dr Xavier Leroy (Photo: Domain Therapeutics)
Based on his widely recognized expertise in GPCRs and immunology, Dr Leroy joined Domain Therapeutics as Chief Technology Officer (CTO) in 2019 to identify and select strategic targets to expand the immuno-oncology pipeline of the company. From now on, Xavier Leroy will lead the Research and will be in charge of turning the company into a clinical stage biopharma.
“Xavier’s tremendous expertise and knowledge of GPCRs and immuno-oncology have already significantly contributed to position the company as a leader in the field of treatments against GPCR-mediated immunosuppression. With new responsibilities and goals in mind, and as part of executive team, Xavier will foster the development of new therapeutic approaches at a time when Domain is accelerating its transition towards a clinical stage company, based on its exclusive pipeline of GPCR therapeutics in immuno-oncology. The whole team is delighted to take this step with Xavier.” said Pascal Neuville, CEO of Domain Therapeutics.
"I am grateful to bring the transformative impact of GPCR science to improve cancer treatment. The prospect of bringing into clinic first-in-class candidates targeting brand new GPCRs in immuno-oncology is very exciting,” said DrXavier Leroy. “I am proud to be part of this adventure and contribute writing the next chapters of Domain Therapeutics, the GPCR-for-IO company”.
After a post-doctoral fellowship at Novartis (Switzerland), Dr Leroy started his career at Axovan AG (Switzerland). He then spent more than thirteen years at Actelion Pharmaceuticals Ltd (now J&J). As associate director, he developed multiple GPCR-targeting programs in the field of neuroscience and inflammation, four in clinical development and one reached the market. More recently as head of drug discovery at Belgium, and now US-based iTeos Therapeutics Inc (Nasdaq: ITOS), he oversaw the development of the company’s immuno-oncology portfolio, bringing an adenosine antagonist candidate into the clinic. Xavier Leroy was instrumental in raising a $75M series B. He is a member of the management committee of the European Cooperation in Science and Technology (COST) where he actively participates in the European Research Network on Signal Transduction (ERNEST).
About Domain Therapeutics
Domain Therapeutics, a biopharmaceutical company operating in France and Canada, is dedicated to the discovery and development of new drug candidates targeting G Protein-Coupled Receptors (GPCRs), one of the most important classes of drug targets. The company focuses on developing high-value drug candidates to tackle GPCR-mediated immunosuppression in immuno-oncology.
www.domaintherapeutics.com
What is the significance of Dr. Xavier Leroy's appointment as CSO of Domain Therapeutics?
Dr. Leroy's appointment is crucial as he will lead research efforts aimed at transitioning Domain Therapeutics into a clinical-stage biopharma, enhancing its immuno-oncology capabilities.
What experience does Dr. Xavier Leroy bring to Domain Therapeutics?
Dr. Leroy has extensive experience in GPCRs and immuno-oncology, having held senior roles at Actelion Pharmaceuticals and successfully developed multiple drug candidates.
How does Dr. Leroy's leadership impact Domain Therapeutics' pipeline?
Under Dr. Leroy's guidance, Domain Therapeutics aims to develop first-in-class immuno-oncology candidates, potentially positioning the company as a leader in GPCR-mediated therapies.
What are the future goals for Domain Therapeutics under Dr. Leroy's leadership?
The company aims to accelerate the development of its GPCR therapeutics pipeline and transition towards clinical-stage operations.
What previous roles did Dr. Leroy hold before becoming CSO?
Before his appointment as CSO, Dr. Leroy served as the Chief Technology Officer of Domain Therapeutics, where he identified strategic targets for the immuno-oncology pipeline.
